Submit Deal

NORGINE BV

HQ - Amsterdam

Summary

Norgine is a European specialist pharmaceutical company that focuses on the development, production, and commercialization of specialist pharmaceutical products in the fields of gastroenterology, hepatology, oncology and supportive care.

Deals Overview

Total Deals4

Valued Deals1

Total Value£ 1.53 B

Avg. Deal Size£ 1.53 B

Market Context

Senior Management

Christopher Bath
CEO
Janneke van der Kamp
CEO
Peter Stein
Chairman

Sort

11 May 2017|Canada|Pharmaceuticals

Target: MERUS LABS INC

Bidder: NORGINE BV

4 Service Providers

2 Target | 2 Bidder

n/a

Value

24 Mar 2020|Denmark|Biotechnology

Target: AZANTA A/S

Bidder: NORGINE BV

5 Service Providers

1 Target | 3 Bidder | 1 Vendor

16 Dealmakers

1 Target | 13 Bidder | 2 Vendor

n/a

Value

26 May 2022|Netherlands|Pharmaceuticals

Target: NORGINE BV

Bidder: GOLDMAN SACHS ASSET MANAGEMENT

13 Service Providers

6 Target | 7 Bidder

81 Dealmakers

41 Target | 40 Bidder

£ 1.53 B

Value

15 Apr 2025|France|Pharmaceuticals

Target: THERAVIA

Bidder: NORGINE BV

6 Service Providers

1 Target | 3 Bidder | 2 Vendor

32 Dealmakers

1 Target | 24 Bidder | 7 Vendor

n/a

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy